The meeting between Gilead and SIPA fostered a deeper understanding and collaboration in protecting IP in the biopharmaceutical field. [Photo/WeChat ID: Shanghai_IPA]

A delegation from US-based biopharmaceutical company Gilead, led by Ivy Tsui, head of intellectual property affairs of Gilead Asia, visited the Shanghai Intellectual Property Administration (SIPA) on Dec 18 for a work exchange meeting.

Yu Chen, deputy director-general of SIPA, welcomed the delegation and provided an overview of the latest developments in Shanghai's IP protection efforts, with a focus on the biopharmaceutical sector. He highlighted the city's policies and measures aimed at enhancing IP protection and encouraged Gilead to offer suggestions and insights to enhance the local IP landscape.

Gilead presented an overview of their business operations and research innovations in China and thanked SIPA for its support in facilitating the growth and development of foreign enterprises in Shanghai.

The discussions also delved into issues surrounding patent protection in the biopharmaceutical industry, a topic of significant interest to both parties.